Role of her3 signaling pathways in er+ and her2+breast cancers

被引：0

作者：

Mishra, Rosalin ^{[1
]}

Alanazi, Samar ^{[1
]}

Patel, Hima ^{[1
]}

Yuan, Long ^{[1
]}

Garrett, Joan T. ^{[1
]}

机构：

[1] Univ Cincinnati, Coll Pharm, Cincinnati, OH USA

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2019-389

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

389

引用

页数：2

共 50 条

[21] Tamoxifen, HER2, and Endoxifen: The Role of CYP2D6 as a Predictor of Tamoxifen Resistance in ER+/HER2+Breast Cancer [J].

Goetz, M. P. ;

Reinicke, K. E. ;

Reid, J. M. ;

Suman, V. J. ;

Kuffel, M. J. ;

Safgren, S. L. ;

Buhrow, S. A. ;

Reynolds, C. A. ;

Jenkins, R. B. ;

Hawse, J. R. ;

Perez, E. A. ;

Ingle, J. N. ;

Ames, M. M. .

CANCER RESEARCH, 2009, 69 (24) :594S-594S

[22] Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers [J].

Campbell, Marcia R. ;

Ruiz-Saenz, Ana ;

Peterson, Elliott ;

Agnew, Christopher ;

Ayaz, Pelin ;

Garfinkle, Sam ;

Littlefield, Peter ;

Steri, Veronica ;

Oeffinger, Julie ;

Sampang, Maryjo ;

Shan, Yibing ;

Shaw, David E. ;

Jura, Natalia ;

Moasser, Mark M. .

CELL REPORTS, 2022, 38 (05)

[23] How population-based data complement trial data in the adjuvant endocrine treatment of ER+/HER2+breast cancers [J].

Dackus, G. M. H. E. ;

Jozwiak, K. ;

Sonke, G. S. ;

Van der Wall, E. ;

Van Diest, P. J. ;

Hauptmann, M. ;

Siesling, S. ;

Linn, S. C. .

CANCER RESEARCH, 2017, 77

[24] Identification of luminal A-like subgroup among ER+/PR+/HER2+breast cancers and its clinical implications [J].

Zhao, S. ;

Jin, X. ;

Jiang, Y-Z ;

Shao, Z-M .

CANCER RESEARCH, 2019, 79 (04)

[25] Targeting focal adhesion kinase in ER+/HER2+breast cancer improves trastuzumab response [J].

Lazaro, Glorianne ;

Smith, Chris ;

Goddard, Lindy ;

Jordan, Nicola ;

McClelland, Richard ;

Barrett-Lee, Peter ;

Nicholson, Robert I. ;

Hiscox, Stephen .

[26] TILs in ER+/HER2-breast cancer [J].

Criscitiello, C. ;

Vingiani, A. ;

Maisonneuve, P. ;

Viale, G. ;

Curigliano, G. .

ANNALS OF ONCOLOGY, 2019, 30 :3-3

[27] The role of non-muscle myosin IIA in HER2+breast cancers [J].

Alanazi, Samar M. ;

Mishra, Rosalin ;

Yuan, Long ;

Patel, Hima ;

Garrett, Joan .

CANCER RESEARCH, 2020, 80 (16)

[28] Treating trastuzumab-resistant HER2+breast cancers with a HER3-targeted nanoparticle [J].

Sims, Jessica D. ;

Tagualm, Michael ;

Hanson, Chris ;

Cui, Xiaogang ;

Medina-Kauwe, Lail K. .

CANCER RESEARCH, 2013, 73

[29] HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+breast cancer [J].

Green, Andrew R. ;

Barros, Fabricio F. T. ;

Abdel-Fatah, Tarek M. A. ;

Moseley, Paul ;

Nolan, Christopher C. ;

Durham, Alice C. ;

Rakha, Emad A. ;

Chan, Stephen ;

Ellis, Ian O. .

BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (01) :33-44

[30] Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer [J].

Osipo, Clodia ;

Meeke, Kathleen ;

Cheng, Dong ;

Weichel, Alyssa ;

Bertucci, Anne ;

Liu, Hong ;

Jordan, V. Craig .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2007, 30 (02) :509-520

← 1 2 3 4 5 →